Drugs / [18F]GP1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02864810 | Aug 2016 → Sep 2017 | thrombotic disease | Asan Foundation | Completed | No outcome recorded |
| Phase 1 | NCT02469376 | Sep 2014 → Dec 2016 | abdominal aortic aneurysm, venous thromboembolism | University of Zurich | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT04156230 | Jan 2020 → Aug 2025 | venous thromboembolism | Dae Hyuk Moon | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]GP1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02864810 ↗ |
| Modality | Diagnostic / imaging agent | “Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.” NCT02469376 ↗ |
| Route | Intravenous | “Intravenous injection” NCT02864810 ↗ |